About Us

Who we are

The Precision Medicine Action for Cancer (PMAC) was created in 2017 and established as a non-profit in April 2025 with the goal of fostering multi-institutional collaboration to consolidate liquid biopsy and precision medicine data from patients with breast cancer and other solid tumors.

The Founders:

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine, Geffen School of Medicine at UCLA

Director, Breast Oncology Program

Assistant Chief (Translational Research), Division of Medical Oncology

Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center

Massimo Cristofanilli, MD, FACP

Professor of Medicine

Associate Director of Precision Medicine, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine

Scientific Director, the Englander Institute of Precision Medicine

President of the Inflammatory Breast Cancer-International Consortium (IBC-IC)

Co-Founder and Past President of the International Society of Liquid Biopsy (ISLB)

Our Team

The organization operates under a structured scientific leadership model, which includes a Steering Committee, comprising one representative from each participating institution per disease area, that reviews study proposals and sets research priorities. There are Working Groups focused on different research aspects; these groups meet monthly to coordinate ongoing projects and generate new study ideas. General Assembly Meetings are conducted monthly involving all members to discuss projects, review progress, and align on strategic objectives. Board of Directors and Officers are responsible for the day-to-day operations, ensuring the sustainability and strategic growth of the PMAC.